IP Library › Granted Patent US 12,742,208
Granted Patent B2
US 12,742,208 · App. 18/106,793 · Granted Sep 22, 2026

Fragmentation for measuring methylation and disease

Inventors: Yuk-Ming Dennis Lo (Homantin, CN); Rossa Wai Kwun Chiu (Shatin, CN); Kwan Chee Chan (Mei Foo Sun Chuen, CN); Peiyong Jiang (Pak Shek Kok, CN); Qing Zhou (Tai Po, CN); Guannan Kang (Shatin, CN); Rong Qiao (Shatin, CN); Lu Ji (Tai Po, CN)
Assignee: Centre for Novostics
C12Q1/6886C12Q1/6851G16B20/00G16B20/30G16B30/10G16B40/00G16B40/20G16B50/00C12Q1/6806C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,742,208
App. No.
18/106,793
Granted
Sep 22, 2026
Kind
B2
Abstract

Fragmentation of cell-free DNA molecules is measured and used for various purposes, including determining methylation, e.g., at a particular site of a DNA molecule, at a particular genomic site in a reference genome for a biological sample (e.g., plasma, serum, urine, saliva) of cell-free DNA of a subject, or for a particular region in the reference genome for the biological sample (also just referred to as a sample). Various types of fragmentation measurements can be used, e.g., end motifs and cleavage profiles. Another purpose is determining a fractional concentration of DNA of a particular tissue type (e.g., clinically-relevant DNA). Another purpose is determining a pathology of a subject using a biological sample including cell-free DNA. The cell-free DNA can be of the subject or of a pathogen (e.g., a virus) in the subject's sample. Sites/regions that are hypermethylated, hypomethylated, 5hmC-enriched, and 5hmC-depleted for a particular tissue type can be used.

Claims (51)

1 . A method for measuring methylation of a CpG site in a genome of a subject using cell-free DNA molecules, the method comprising:

analyzing a plurality of cell-free DNA molecules from a biological sample of the subject, wherein the plurality of cell-free DNA molecules is not treated using a process that differentially modifies nor differentially recognizes DNA molecules depending on their methylation status, wherein the analyzing includes at least one selected from a group consisting of massively parallel sequencing and PCR that provides sequence reads of the plurality of cell-free DNA molecules, and wherein analyzing each cell-free DNA molecule of the plurality of cell-free DNA molecules includes:

determining, using one or more of the sequence reads, a genomic position in a reference genome corresponding to at least one end of the cell-free DNA molecule;

determining, using the sequence reads, a first amount of the plurality of cell-free DNA molecules from the biological sample ending at a first position within a window around the CpG site, the first position being between-1 to +1 position of the window, the CpG site having a 0 position being C;

determining one or more other amounts of the plurality of cell-free DNA molecules, and wherein the first amount, the one or more other amounts, or both include one or more cell-free DNA molecules of the plurality of cell-free DNA molecules that end at a position (1) that is in a region including the CpG site and (2) that is other than the 0 position for the CpG site or any other CpG site; and

determining, using the first amount and the one or more other amounts, a classification for methylation of the CpG site in the genome of the subject.

2 . The method of claim 1 , further comprising:

determining a second amount of cell-free DNA molecules ending at a second position within the window around the CpG site, the second position being different than the first position, the one or more other amounts including the second amount.

3 . The method of claim 2 , wherein the first position is the 0 position, and wherein the second position is at +1 or −1 from the CpG site.

4 . The method of claim 2 , wherein the window is at least −2 to +2 from the CpG site.

5 . The method of claim 2 , wherein determining the classification includes:

determining a separation value using the first amount and the second amount; and

comparing the separation value to a calibration value, wherein the calibration value is determined using cell-free DNA molecules that are from one or more calibration samples and that are located at CpG sites having known classifications.

6 . The method of claim 5 , wherein the classification is a quantitative value, and wherein comparing the separation value to the calibration value includes comparing the separation value to a calibration function.

7 . The method of claim 6 , wherein the quantitative value is a range that is 30% or less.

8 . The method of claim 2 , wherein the CpG site is a first CpG site and the classification is a first classification, and wherein the window includes a second CpG site and at least two positions other than the first CpG site and the second CpG site, and the method further comprising:

determining a third amount of cell-free DNA molecules ending at the second CpG site;

for each position of the at least two positions within the window:

determining a respective amount of cell-free DNA molecules ending at the position, thereby determining respective amounts including the second amount, wherein the at least two positions include the first position;

generating a feature vector including the respective amounts, the first amount, and the third amount; and

inputting the feature vector into a machine learning model as part of determining the classification for the first CpG site and determining a second classification of the second CpG site, wherein the machine learning model is trained using cell-free DNA molecules located within windows around CpG sites having known classifications.

9 . The method of claim 1 , wherein the window includes at least two positions other than the first position, the method further comprising:

for each position of the at least two positions within the window:

determining a respective amount of cell-free DNA molecules ending at the position; and

comparing the first amount of cell-free DNA molecules ending at the first position to the respective amount of cell-free DNA molecules ending at the position as part of determining the classification, wherein the one or more other amounts include the respective amount.

10 . The method of claim 1 , wherein the window includes at least two positions other than the first position, the method further comprising:

for each position of the at least two positions within the window:

determining a respective amount of cell-free DNA molecules ending at the position, thereby determining respective amounts, wherein the one or more other amounts include the respective amount;

generating a feature vector including the respective amounts and the first amount; and

inputting the feature vector into a machine learning model as part of determining the classification, wherein the machine learning model is trained using cell-free DNA molecules located within windows around CpG sites having known classifications.

11 . The method of claim 10 , wherein the feature vector forms a matrix with each row corresponding to a base of a strand, and wherein a column includes a non-zero amount in the row corresponding to the base at a respective position.

12 . The method of claim 10 , wherein the machine learning model is a convolutional neural network.

13 . The method of claim 10 , wherein the first position and the at least two positions include all positions within the window, the window being at least +4 to −4 from the CpG site.

14 . The method of claim 10 , wherein the machine learning model uses a sequence context within the window.

15 . The method of claim 14 , wherein the machine learning model is trained for the sequence context within the window.

16 . The method of claim 14 , wherein the feature vector includes the sequence context.

17 . The method of claim 1 , wherein the classification for methylation indicates that the CpG site is in a hypermethylated state or a hypomethylated state for the cell-free DNA molecules at the CpG site, wherein the hypermethylated state indicates a methylation density above a first threshold that is at least 70%, and wherein the hypomethylated state indicates the methylation density below a second threshold that is 30% or less.

18 . The method of claim 1 , wherein the first amount is normalized.

19 . The method of claim 18 , wherein the normalization uses the number of the plurality of cell-free DNA molecules ending within a region including the CpG site, wherein the one or more other amounts include the number of the plurality of cell-free DNA molecules ending within the region including the CpG site.

20 . The method of claim 18 , wherein the normalization uses a number of the plurality of cell-free DNA molecules covering the CpG site, wherein the one or more other amounts include the number of the plurality of cell-free DNA molecules ending within a region including the CpG site.

21 . The method of claim 18 , wherein the normalization uses an average or median depth of the plurality of cell-free DNA molecules in a region including the CpG site, wherein the one or more other amounts includes the average or median depth.

22 . The method of claim 1 , further comprising:

determining, using the first amount, another classification for methylation of a different CpG site in the genome of the subject, the different CpG site being within 600 nucleotides (nt) downstream from the 5′ end of the CpG site.

23 . The method of claim 1 , wherein analyzing the plurality of cell-free DNA molecules includes sequencing the plurality of cell-free DNA molecules.

24 . The method of claim 1 , wherein analyzing the plurality of cell-free DNA molecules includes using PCR.

25 . The method of claim 24 , wherein the PCR targets sequences in a repeat region.

26 . The method of claim 1 , wherein analyzing the plurality of cell-free DNA molecules includes analyzing at least 10,000 cell-free DNA molecules.

27 . The method of claim 1 , wherein determining the genomic position of each of the plurality of cell-free DNA molecules includes aligning, using a computer system, one or more sequence reads of the cell-free DNA molecule to the reference genome.

28 . The method of claim 27 , wherein the subject is a human, and wherein the reference genome is a reference human genome.

29 . The method of claim 1 , further comprising:

outputting, by a computer system, the classification for methylation of the CpG site.

Assignments (2)
CHANGE OF NAME Recorded Feb 11, 2025
From: CENTRE FOR NOVOSTICS LIMITED
To: CENTRE FOR NOVOSTICS
Reel/Frame 070177/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2023
From: LO, YUK-MING DENNIS; CHIU, ROSSA WAI KWUN; CHAN, KWAN CHEE; JIANG, PEIYONG; ZHOU, QING; KANG, GUANNAN; QIAO, RONG; JI, LU
To: CENTRE FOR NOVOSTICS LIMITED
Reel/Frame 062679/0576 →
Continuity (4)
Provisional Application 63400244 · Aug 23, 2022
Provisional Application 63328710 · Apr 7, 2022
Provisional Application 63307622 · Feb 7, 2022
Related Publication 20230313314A1 · Oct 5, 2023
References Cited (83)
US 20140080715A1 · Lo et al. · 2014 [cited by applicant]
US 20180149636A1 · Lo et al. · 2018 [cited by applicant]
US 20180208999A1 · Lo et al. · 2018 [cited by applicant]
US 20180237863A1 · Namsaraev et al. · 2018 [cited by applicant]
US 20200005899A1 · Nicula et al. · 2020 [cited by applicant]
US 20200199656A1 · Lo et al. · 2020 [cited by applicant]
US 20210189494A1 · Lo et al. · 2021 [cited by applicant]
US 20210238668A1 · Lo et al. · 2021 [cited by applicant]
US 20210238694A1 · Gross et al. · 2021 [cited by applicant]
US 20210254142A1 · Lo et al. · 2021 [cited by applicant]
US 20220010353A1 · Lo et al. · 2022 [cited by applicant]
US 20220396838A1 · Lo et al. · 2022 [cited by applicant]
CN 112735531A · 2021 [cited by applicant]
WO 2018027176A1 · 2018 [cited by applicant]
WO 2018081130A1 · 2018 [cited by applicant]
WO 2018137685A1 · 2018 [cited by applicant]
WO 2019020057A1 · 2019 [cited by applicant]
WO 2019159184A1 · 2019 [cited by applicant]
WO 2020125709A1 · 2020 [cited by applicant]
WO 2021032060A1 · 2021 [cited by applicant]
WO 2021155831A1 · 2021 [cited by applicant]
WO 2021174072A1 · 2021 [cited by applicant]
WO 2022214051A1 · 2022 [cited by applicant]
WO 2024007971A1 · 2024 [cited by applicant]
WO 2024022529A1 · 2024 [cited by applicant]
WO 2024125660A1 · 2024 [cited by applicant]
Peng et al., Identifying the tissues-of-origin of circulating cell-free DNAs is a promising way in noninvasive diagnostics, 2021, Briefings in Bioinformatics, 22(3), p. 1-20 (Year: 2021). [cited by examiner]
Brunner et al., Distinct DNA methylation patterns characterize differentiated human embryonic stem cells and developing human fetal liver, 2009, Genome Research, 19, p. 1044-1056 and suppl (Year: 2009). [cited by examiner]
Mair et al., Cell-free DNA technologies for the analysis of brain cancer, British Journal of Cancer, 2021, p. 371-378 (Year: 2021). [cited by examiner]
Valencia et al., Analytical Performance Assessment of Two Clinical Exome Pipelines: The CCHMC Experience, 2014, Journal of Molecular Diagnostics, p. 699-789. (Year: 2014). [cited by examiner]
Zheng et al., Prediction of genome-wide DNA methylation in repetitive elements, 2017, Nucleic Acids Research, 45(15), p. 8697-8711 (Year: 2017). [cited by examiner]
Galardi et al., Cell-Free DNA-Methylation-Based Methods and Applications in Oncology, Biomolecules, 2020, 10, 1677, p. 1-23 (Year: 2020). [cited by examiner]
Wu et al., Statistical Quantification of Methylation Levels by Next-Generation Sequencing, 2011, PLoS ONE, 6(6), p. 1-12 (Year: 2011). [cited by examiner]
Genome Research, CSH Press, vol. 31, No. 11, Nov. 2021, 1 page. [cited by applicant]
U.S. Appl. No. 17/993,845, filed Nov. 23, 2022. [cited by applicant]
An et al., DNA Methylation Analysis Explores the Molecular Basis of Plasma Cell-Free DNA Fragmentation, Nature Communications, vol. 14, Article No. 287, Jan. 18, 2023, pp. 1-12. [cited by applicant]
Brukner et al., Sequence-Dependent Bending Propensity of DNA as Revealed by DNase I: Parameters for Trinucleotides, The European Molecular Biology Organization Journal, vol. 14, No. 8, Apr. 18, 1995, pp. 1812-1818. [cited by applicant]
Han et al., Nuclease Deficiencies Alter Plasma Cell-Free DNA Methylation Profiles, Genome Research, vol. 31, No. 11, Sep. 1, 2021, pp. 2008-2021. [cited by applicant]
Kim et al., Determination of Fetal DNA Fraction from the Plasma of Pregnant Women Using Sequence Read Counts, Prenatal Diagnosis, vol. 35, No. 8, Aug. 3, 2015, pp. 810-815. [cited by applicant]
Lazarovici et al., Probing DNA Shape and Methylation State on a Genomic Scale with DNase I, Proceedings of the National Academy of Sciences of the United States of America, vol. 110, No. 16, Apr. 16, 2013, pp. 6376-6381. [cited by applicant]
Lazarovici et al., Supporting Information: Probing DNA Shape and Methylation State on a Genomic Scale with DNase I, Proceedings of the National Academy of Sciences of the United States of America, vol. 110, No. 16, Apr.… [cited by applicant]
Liu et al., Abstract 5689: Identify Tissue-of-Origin in Cancer cfDNA by Whole Genome Sequencing, Cancer Research, vol. 77, Suppl. 13, Jul. 1, 2017, 1 page. [cited by applicant]
Liu, At the dawn: Cell-Free DNA Fragmentomics and Gene Regulation, British Journal of Cancer, vol. 126, No. 3, Feb. 2022, pp. 379-390. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed May 10, 2023 in International Patent Application No. PCT/CN2023/074730. 7 pages. [cited by applicant]
Final Office Action mailed Jun. 4, 2024 in U.S. Appl. No. 18/117,992, filed Mar. 6, 2023. 29 pages. [cited by applicant]
Song, Ping et al.; “Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics”; HHS Public Access Author Manuscript; Nature Biomedical Engineering; 2022; vol. 6, No. 3; pp. 23… [cited by applicant]
Non-Final Office Action mailed Feb. 7, 2024 in U.S. Appl. No. 18/117,992, filed Mar. 6, 2023. 58 pages. [cited by applicant]
Cervena, Klara et al.; “Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review”; Mutation Research—Reviews in Mutation Research; 2019; vol. 781; pp. 100-129. [cited by applicant]
Ehrlich; Melanie; “DNA hypomethylation in cancer cells”; Epigenomics; 2009; vol. 1, No. 2; pp. 239-259. [cited by applicant]
Non-Final Office Action mailed Mar. 21, 2024 in U.S. Appl. No. 18/118,024, filed Mar. 6, 2023. 47 pages. [cited by applicant]
Final Office Action mailed Oct. 18, 2024 in U.S. Appl. No. 18/118,024, filed Mar. 6, 2023. 55 pages. [cited by applicant]
Leal, Alessandro et al.; “Tissue and Cell-Free DNA-Based Epigenomic Approaches for Cancer Detection”; Clinical Chemistry; 2020; vol. 66, No. 1; pp. 105-116. [cited by applicant]
Examination Report under Section 18(3) dated Dec. 2, 2024 in GB Patent Application No. 2411921.6. 6 pages. [cited by applicant]
Office Action dated Dec. 2, 2024 in MX Patent Application No. MX/a/2024/009647, with English translation. 13 pages. [cited by applicant]
Substantive Examination Adverse Report mailed Dec. 13, 2024 in MY Patent Application PI2024004348. 4 pages. [cited by applicant]
English translation of Office Action dated Jan. 31, 2025 in EA Patent Application No. 202492039. 2 pages. [cited by applicant]
Office Action dated Feb. 10, 2025 in IL Patent Application No. 314466. 4 pages. [cited by applicant]
Office Action dated Mar. 23, 2025 in IL Patent Application No. 317918. 4 pages. [cited by applicant]
Written Opinion dated Mar. 26, 2025 in SG Patent Application No. 11202404810X. 8 pages. [cited by applicant]
Combined Search and Examination Report under Sections 17 & 18(3) dated Apr. 9, 2025 in GB Patent Application No. 2501650.2. 4 pages. [cited by applicant]
Combined Search and Examination Report under Sections 17 & 18(3) dated Apr. 9, 2025 in GB Patent Application No. 2501648.6. 5 pages. [cited by applicant]
Jin, Chao et al.; “Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection”; Molecular Oncology; 20… [cited by applicant]
Office Action dated Apr. 10, 2025 in IL Patent Application No. 317917. 6 pages. [cited by applicant]
Extended European Search Report dated Jun. 11, 2025 in EP Patent Application No. 25152220.7. 12 pages. [cited by applicant]
Zhou, Qing et al.; “Epigenetic analysis of cell-free DNA by fragmentomic profiling”; PNAS; 2022; vol. 119, No. 44; e2209852119; pp. 1-12. [cited by applicant]
Jiang, Peiyong et al.; “Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation”; Cancer Discovery; May 2020; vol. 10, No. 5; pp. 664-673 (11 total pages). [cited by applicant]
Extended European Search Report dated Jun. 13, 2025 in EP Patent Application No. 23749362.2. 12 pages. [cited by applicant]
Noë, Michaël et al.; “DNA methylation and gene expression as determinants of genome-wide cell-free DNA fragmentation”; Nature Communications; 2024; vol. 15, No. 6690; pp. 1-11. [cited by applicant]
Extended European Search Report dated Jun. 13, 2025 in EP Patent Application No. 25152221.5. 12 pages. [cited by applicant]
Extended European Search Report dated Jun. 13, 2025 in EP Patent Application No. 25152224.9. 13 pages. [cited by applicant]
English translation of Office Action dated Jul. 10, 2025 in EA Patent Application No. 202591071. 2 pages. [cited by applicant]
Office Action dated Jul. 14, 2025 in IL Patent Application No. 314466. 4 pages. [cited by applicant]
Non-Final Office Action mailed Aug. 6, 2025 in U.S. Appl. No. 18/118,024, filed Mar. 6, 2023. 33 pages. [cited by applicant]
Ballester, Leomar Y. et al.; “Advances in clinical next-generation sequencing: target enrichment and sequencing technologies”; Expert Review of Molecular Diagnostics; 2016; vol. 16, No. 3; pp. 357-372. [cited by applicant]
Tay, Timothy Kwang Yong et al.; “Liquid Biopsy in Breast Cancer: A Focused Review”; Archives of Pathology & Laboratory Medicine; Jun. 2021; vol. 145, No. 6; pp. 678-686. [cited by applicant]
Office Action dated Feb. 10, 2026 in AE Patent Application No. P2024-02042. 6 pages. [cited by applicant]
Koval, Anastasia P. et al.; “The Detection of Cancer Epigenetic Traces in Cell-Free DNA”; Frontiers in Oncology; Apr. 2021; vol. 11, Article 662094; pp. 1-10. [cited by applicant]
Final Office Action mailed Feb. 11, 2026 in U.S. Appl. No. 18/118,024, filed Mar. 6, 2023. 30 pages. [cited by applicant]
Illumina; “An introduction to Next-Generation Sequencing Technology”; 2017; [retrieved from the Internet: < https://www.illumina.com/content/dam/illumina-marketing/documents/products/illumina_sequencing_introduction.pdf… [cited by applicant]
Gorgannezhad, Lena et al.; “Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advanced in detection technologies”; Lab on a Chip; 2018; vol. 18, No. 8; pp. 1174-1196. [cited by applicant]
Patent Acts 1977: Search under Section 17 and deferred examination dated Mar. 10, 2026 in GB Patent Application No. 2518541.4. 3 pages. [cited by applicant]
English translation of Office Action mailed Mar. 17, 2026 in JP Patent Application No. 2024-546428. 6 pages. [cited by applicant]
English translation of Office Action and Search Report mailed May 27, 2026 in TW Patent Application No. 112104317. 6 pages. [cited by applicant]